| 刘亚玮,赵春艳,王春仙,李建坤,肖春风.舒洛地特与缬沙坦治疗Ⅲ期、Ⅳ期糖尿病肾病的临床疗效[J].现代生物医学进展英文版,2017,17(19):3664-3667. |
| 舒洛地特与缬沙坦治疗Ⅲ期、Ⅳ期糖尿病肾病的临床疗效 |
| Clinical Effect of Sulodexide Combined with Valsartan on Patients with Stage Ⅲ and Ⅳ Diabetic Nephropathy |
| Received:November 26, 2016 Revised:December 20, 2016 |
| DOI：10.13241/j.cnki.pmb.2017.19.015 |
| 中文关键词: 舒洛地特 缬沙坦 糖尿病肾病 临床疗效 |
| 英文关键词: Sulodexide Valsartan Diabetic nephropathy Clinical efficacy |
| 基金项目:河北省卫生计生委发展计划项目（20160281） |
|
| Hits: 324 |
| Download times: 159 |
| 中文摘要: |
| 摘要 目的：观察和比较舒洛地特(SDX)联合缬沙坦(VAL)治疗Ⅲ期、Ⅳ期糖尿病肾病(DN)的临床效果及对患者肝肾功能、凝血功能的影响。方法：选取我院2014年6月~2016年6月收治的146例DN患者，按照随机数字表法均分为两组。对照组予VAL治疗，观察组在此基础上联合SDX治疗，记录比较两组临床疗效，治疗前后肝肾功能指标和凝血功能指标以及治疗期间不良反应的发生情况。结果：经3个月治疗后，观察组总有效率为95.9%，明显高于对照组的84.9%(P<0.05)。两组治疗前后血清γ-GT、ALT、BUN、Scr水平及APTT、PT值组内及组间比较差异均无统计学意义(P>0.05)。与治疗前相比，两组治疗后24h UAlb、尿β1-MG和血浆FIB水平均显著下降(P<0.01)，且观察组治疗后24 h UAlb、尿α1-MG和血浆FIB水平降低程度均显著高于对照组同期(P<0.01)。观察组不良反应率为9.6%，较对照组(8.2%)相比差异无统计学意义(P>0.05)。结论：应用SDX联合VAL治疗Ⅲ、Ⅳ期糖尿病肾病患者更能显著提高其临床疗效，提高肾功能，且对患者肝功能及凝血功能均无显著影响。 |
| 英文摘要: |
| ABSTRACT Objective: To observe and compare the effect of sulodexide(SDX) combined with valsartan (VAL) on the efficacy, liver, kidney function and coagulation function of patients with stage Ⅲ and Ⅳ diabetic nephropathy (DN). Methods: 146 cases of patients with DN in our hospital from June 2014 to June 2016 were selected and randomly divided into two groups. The control group was treated by VAL, the observation group was treated by to SDX on the basis of control group. The clinical effect, liver, kidney function and coagulation function before and after treatment as well as the occurrence of adverse reaction during therapy period of both groups were compared. Results: After 3 months of therapy, the overall effectiveness rate of observation group was 95.9%, which was significantly higher than that of the control group(84.9%, P<0.05). No significant difference was found in the serum γ-GT, ALT, BUN, Scr levels, APTT, PT value before and after therapy between two groups(P>0.05). The 24 h UAlb, urine α1-MG and plasma FIB after therapy of both groups were significantly lower than those before therapy(P<0.01), which were significantly lower in the observation group than those of the control group at the same time(P<0.01). No statistical difference was found in the incidence of adverse reactions between two groups(P>0.05). Conclusion: SDX combined with VAL significantly improve the clinical effect of patients with stage Ⅲ and Ⅳ diabetic nephropathy with no significant impact on the liver function and coagulation function. |
|
View Full Text
View/Add Comment Download reader |
| Close |
